The FGFR4 gene is part of an 8-gene mTOR signature, correlating with increased PD-1/L1 expression and indicating potential for predicted improved survival outcomes in patients treated with immune checkpoint inhibitors across various cancer types 293. Here, PDCD1 is linked to cancer.